Neumonía por COVID-19 y uso de tocilizumab

Ursula Cáceres-Bernaola; Claudia Becerra-Núñez; Sabina Mendívil-Tuchía de Tai; Jorge Ravelo-Hernández

doi:10.15381/anales.v81i2.17893

COVID-19 pneumonia and tocilizumab use

Authors

Ursula Cáceres-Bernaola Sección de Medicina Interna, Hospital Central de la Fuerza Aérea del Perú. Lima, Perú. https://orcid.org/0000-0001-5057-1651
Claudia Becerra-Núñez Sección de Medicina Interna, Hospital Central de la Fuerza Aérea del Perú. Lima, Perú. https://orcid.org/0000-0002-6799-6100
Sabina Mendívil-Tuchía de Tai Sección de Medicina Interna, Hospital Central de la Fuerza Aérea del Perú. Lima, Perú. https://orcid.org/0000-0002-7796-9376
Jorge Ravelo-Hernández Sección de Medicina Interna, Hospital Central de la Fuerza Aérea del Perú. Lima, Perú. https://orcid.org/0000-0001-9179-3541

DOI:

https://doi.org/10.15381/anales.v81i2.17893

Keywords:

Pneumonia, COVID-19, Interleukin-6, Tocilizumab

Abstract

We present the case of a 44-year-old male patient, health personnel with high blood pressure, who had contact with patients with COVID-19 pneumonia. He had rapidly clinically-radiologically progressive lung involvement, received evidence-based treatment at admission, and an interleukin-6 receptor antagonist (tocilizumab) for compassionate use, obtaining a favorable clinical response.

Downloads

PDF (Spanish)

Published

2020-07-03

Issue

Vol. 81 No. 2 (2020)

Section

Reporte de Casos

License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

Cáceres-Bernaola U, Becerra-Núñez C, Mendívil-Tuchía de Tai S, Ravelo-Hernández J. COVID-19 pneumonia and tocilizumab use. An Fac med [Internet]. 2020 Jul. 3 [cited 2025 May 25];81(2). Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/17893

Download Citation